A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D-3 is revealed using a novel LC-MS/MS assay

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, United States.
Steroids (Impact Factor: 2.64). 01/2012; 77(5):477-83. DOI: 10.1016/j.steroids.2012.01.007
Source: PubMed


The vitamin D(3) catabolizing enzyme, CYP24, is frequently over-expressed in tumors, where it may support proliferation by eliminating the growth suppressive effects of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)). However, the impact of CYP24 expression in tumors or consequence of CYP24 inhibition on tumor levels of 1,25(OH)(2)D(3)in vivo has not been studied due to the lack of a suitable quantitative method. To address this need, an LC-MS/MS assay that permits absolute quantitation of 1,25(OH)(2)D(3) in plasma and tumor was developed. We applied this assay to the H292 lung tumor xenograft model: H292 cells eliminate 1,25(OH)(2)D(3) by a CYP24-dependent process in vitro, and 1,25(OH)(2)D(3) rapidly induces CYP24 expression in H292 cells in vivo. In tumor-bearing mice, plasma and tumor concentrations of 1,25(OH)(2)D(3) reached a maximum of 21.6 and 1.70ng/mL, respectively, following intraperitoneal dosing (20μg/kg 1,25(OH)(2)D(3)). When co-administered with the CYP24 selective inhibitor CTA091 (250μg/kg), 1,25(OH)(2)D(3) plasma levels increased 1.6-fold, and tumor levels increased 2.6-fold. The tumor/plasma ratio of 1,25(OH)(2)D(3) AUC was increased 1.7-fold by CTA091, suggesting that the inhibitor increased the tumor concentrations of 1,25(OH)(2)D(3) independent of its effects on plasma disposition. Compartmental modeling of 1,25(OH)(2)D(3) concentration versus time data confirmed that: 1,25(OH)(2)D(3) was eliminated from plasma and tumor; CTA091 reduced the elimination from both compartments; and that the effect of CTA091 on tumor exposure was greater than its effect on plasma. These results provide evidence that CYP24-expressing lung tumors eliminate 1,25(OH)(2)D(3) by a CYP24-dependent process in vivo and that CTA091 administration represents a feasible approach to increase tumor exposure to 1,25(OH)(2)D(3).

1 Follower
45 Reads
  • Source
    • "Evidence from animal model studies and in vitro cell culture suggest that vitamin D may play a beneficial role in pulmonary inflammation. Vitamin D status may be an important issue for lung cancer prevention (Beumer et al., 2012; Norton and O'Connell, 2012; Zhang et al., 2012). With the prospect of more effective therapeutic options for advanced stage disease, the characterization of new methodologies for monitoring patients' pre-/post-therapy is of interest. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Lung cancer is the leading cause of cancer mortality in the world. Many factors can protect against or facilitate the development of the cancer. A TNF family member TRAIL, has a complex physiological role beyond that of merely activating the apoptotic pathway in cancer cells. Vitamin D is converted to its active form locally in the lung, and is also thought to play an important role in lung health. Our goal was to investigate the possible clinical significance of serum sTRAIL and 1,25-dihydroxyvitamin D(3) levels in patients with non-small cell lung cancer (NSCLC). Materials and Method: 18 consecutive adenocarcinoma and 22 squamous cell carcinoma patients with stage-IV non-small cell lung cancer referred to our institute were included in this study. There were 12 men and 6 women, with ages ranging from 38 to 97 (mean 60.5) years with adenocarcinoma, and 20 men and 2 women, with ages ranging from 46 to 80 (mean 65) years with squamous cell carcinoma. Serum levels of sTRAIL and 1,25-dihydroxyvitamin D(3) were measured in all samples at the time of diagnosis. Results: sTRAIL levels in NSCLC patients were higher than in the control group. Although there was no correlation between patient survival and sTRAIL levels, the highest sTRAIL levels were correlated with age and cigarette smoking in the adenocarcinoma patients. sTRAIL level in healthy individuals were correlated with serum 1,25-dihydroxyvitamin D(3). Conclusions: Serum sTRAIL concentrations were increased in NSCLC patients, and correlated with age and smoking history, but not with overall survival.
    Asian Pacific journal of cancer prevention: APJCP 09/2013; 14(8):4949 - 4952. DOI:10.7314/APJCP.2013.14.8.4949 · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The active vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) plays a major role in regulating calcium homeostasis and bone mineralization. 1,25(OH)(2)D(3) also modulates cellular proliferation and differentiation in a variety of cell types. 24-Hydroxylase, encoded by the CYP24A1 gene, is the key enzyme which converts 1,25(OH)(2)D(3) to less active calcitroic acid. Nearly all cell types express 24-hydroxylase, the highest activity being observed in the kidney. There is increasing evidence linking the incidence and prognosis of certain cancers to low serum 25 (OH)D(3) levels and high expression of vitamin D 24-hydroxylase supporting the idea that elevated CYP24A1 expression may stimulate degradation of vitamin D metabolites including 25-(OH)D(3) and 1,25(OH)(2)D(3). The over expression of CYP24A1 in cancer cells may be a factor affecting 1,25(OH)(2)D(3) bioavailability and anti-proliferative activity pre-clinically and clinically. The combination of 1,25(OH)(2)D(3) with CYP24A1 inhibitors enhances 1,25(OH)(2)D(3) mediated signaling and anti-proliferative effects and may be useful in overcoming effects of aberrant CYP24 expression. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
    The Journal of steroid biochemistry and molecular biology 10/2012; 136(1). DOI:10.1016/j.jsbmb.2012.09.031 · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D has broad range of physiological functions and anti-tumor effects. 24-hydroxylase, encoded by the CYP24A1 gene, is the key enzyme for degrading many forms of vitamin D including the most active form, 1,25D3. Inhibition of CYP24A1 enhances 1,25D3 anti-tumor activity. In order to isolate regulators of CYP24A1 expression in prostate cancer cells, we established a stable prostate cancer cell line PC3 with the CYP24A1 promoter driving luciferase expression to screen a small molecular library for compounds that inhibit CYP24A1 promoter activity. From this screening, we identified, 4,5,6,7-tetrabromobenzimidazole (TBBz), a protein kinase CK2 (CSNK2A2) selective inhibitor as a disruptor of CYP24A1 promoter activity. We show that TBBz specifically inhibits CYP24A1 promoter activity induced by 1,25D3 in prostate cancer cells. In addition, TBBz downregulates endogenous CYP24A1 mRNA level in PC3 cells. Furthermore, siRNA-mediated CK2 knockdown reduces 1,25D3 induced CYP24A1 mRNA expression in PC3 cells. These results suggest that CK2 contributes to 1,25D3 mediated target gene expression. Lastly, inhibition of CK2 by TBBz or CK2 siRNA significantly enhanced 1,25D3 mediated anti-proliferative effect in vitro and in vivo in a xenograft model. In summary, our findings reveal that protein kinase CK2 is involved in the regulation of CYP24A1 expression by 1,25D3 and CK2 inhibition enhances the 1,25D3 mediated anti-tumor effect.
    Cancer Research 01/2013; 73(7). DOI:10.1158/0008-5472.CAN-12-4119 · 9.33 Impact Factor